Klebsiella pneumoniae K1 Specific Neutra™ Antibody Products
Product listAccelerate Your Research and Development!
Are you currently facing challenges like long drug development cycles, difficulty in rapid K1 strain detection, or limited success in developing therapeutic antibodies against hypervirulent pathogens? Our K. pneumoniae K1 Specific Neutra™ Antibody Products help you accelerate targeted therapy development, obtain highly specific diagnostic tools, and neutralize critical K1 virulence factors through innovative antibody engineering techniques focusing on capsular polysaccharides.
Contact our team to get an inquiry now!
Introduction of K. pneumoniae K1
Klebsiella pneumoniae is an opportunistic pathogen traditionally known for causing nosocomial infections. However, the emergence of the hypervirulent phenotype (hvKp), characterized by the K1 and K2 capsular serotypes, has transformed it into a global public health threat, causing severe community-acquired diseases. The K1 serotype is particularly virulent and is responsible for severe infections such as pyogenic liver abscesses, endophthalmitis, and even central nervous system infections. The hypervirulence is primarily mediated by the capsular polysaccharide (CPS), a thick layer surrounding the bacterial cell. For K1 strains, this highly negatively charged capsule is the main armor, effectively preventing phagocytosis by host immune cells and inhibiting complement cascade deposition. The genes involved in CPS synthesis are organized in the cps gene cluster, which is highly conserved among K1 strains. This robust antiphagocytic function allows K1 strains to survive and disseminate rapidly within the host, leading to invasive disease. Understanding the precise molecular interaction between the antibody and this K1 CPS is foundational for developing effective countermeasures.
Fig.1 Diseases caused by K. pneumoniae hypervirulent phenotype.1
Antibodies Against K. pneumoniae K1
Antibodies specifically targeting the K1 capsular polysaccharide are invaluable reagents with broad potential across research, diagnostics, and therapeutics, primarily due to their ability to bind to and neutralize bacterial virulence.
Key Applications of K1 Specific Antibodies:
- Serological Identification: Highly specific K1 antibodies are used in clinical assays (e.g., agglutination) for the rapid serotyping of hypervirulent K1 strains, which is crucial for guiding clinical treatment decisions.
- Passive Immunization Research: In therapeutic research, neutralizing antibodies opsonize the bacteria, facilitating phagocytosis by immune cells and reversing the primary virulence mechanism. This is foundational for developing humanized monoclonal antibodies for passive immunotherapy against severe, drug-resistant infections.
- Vaccine Efficacy Testing: These antibodies are essential for measuring the functional response and opsonophagocytic activity (OPA) of capsular polysaccharide-based vaccine candidates, requiring a high-quality reference antibody.
- Immunohistochemistry (IHC) and Immunofluorescence (IF): They localize K1 bacterial aggregates in infected tissue models, offering critical insights into pathogenesis and tissue tropism.
Why Choose Us?
Choosing Creative Biolabs means partnering with 20 years of high-affinity antibody engineering expertise, offering reliability essential for tackling hypervirulent pathogens.
Key Advantages of Creative Biolabs' Antibody Products:
- Superior K1 Specificity: Rigorous counter-screening against other prevalent serotypes (e.g., K2) minimizes cross-reactivity, guaranteeing results specific to the dangerous K1 strain.
- Validated Neutralizing Efficacy: Our Neutra™ products are functionally validated in neutralization assays, confirming the antibody's ability to block the K1 capsule's anti-phagocytic activity—superior to mere binding data.
- High Lot Consistency: Stringent quality control protocols ensure reagent reproducibility, a critical factor for long-term development projects.
- Supporting Data and Expertise: Internal validation reports and peer-reviewed studies demonstrate reliability in complex biological matrices, reflecting our deep understanding of capsular polysaccharide targets.
- Customization: We offer custom conjugation, fragmentation, and scale-up services to meet your precise diagnostic or therapeutic formulation demands.
FAQs
Q: What is the primary function of the capsular polysaccharide (CPS)?
A: CPS is the main virulence factor, forming a protective, thick outer layer that prevents phagocytosis and inhibits the complement system, allowing the bacteria to evade the host immune response and cause invasive disease.
Q: How do these targeted antibodies function therapeutically?
A: They function primarily through opsonization and neutralization, binding specifically to the capsule to "flag" the pathogen for destruction by professional phagocytic cells (macrophages and neutrophils) and interfering with the capsule's ability to repel immune effectors.
Q: Are the antibodies suitable for complex matrices (e.g., serum/tissue)?
A: Yes, these high-specificity antibodies are suitable for assays in complex matrices, though assay optimization remains essential to ensure accurate signal detection and quantification.
Q: What is the most critical technical consideration for diagnostic assay development?
A: The most critical consideration is ensuring the antibody's high affinity and specificity. Cross-reactivity with other, less virulent serotypes must be absolutely minimized to prevent false positives and maintain diagnostic power.
Q: Can these reagents be used to study genetic regulation of the capsular target?
A: While they target the expressed polysaccharide, they are powerful downstream tools. Researchers can indirectly measure the functional output of genetic manipulations (e.g., changes in cps gene cluster expression) by quantifying the expressed capsule amount.
Access the Creative Biolabs Edge – Request Your Quote Now
REFERENCE
- Hetta, Helal F et al. "Hypervirulent Klebsiella pneumoniae: Insights into Virulence, Antibiotic Resistance, and Fight Strategies Against a Superbug." Pharmaceuticals (Basel, Switzerland) vol. 18,5 724. 15 May. 2025, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ph18050724
